Abstract
Monoclonal antibodies have undergone a radical evolutionary journey over the last 25 years, with advances in molecular biology, process development and drug formulation underpinning their rise to becoming one of the most efficacious and economically important class of drug today. The success of antibodies for the treatment of rheumatological conditions, such as rheumatoid arthritis in particular, has driven the biopharmaceutical industry to optimize all aspects of therapeutic antibody discovery and development, in order to provide further benefits for patients over and above marketed treatments, via increased clinical efficacy and patient convenience. Recent advances in many of the key aspects of antibody design that are driving this evolution, such as affinity optimization, effector function modulation, pharmacokinetic engineering, as well as developments in subcutaneous drug delivery, are reviewed here.
Keywords: Antibody, rheumatology, affinity maturation, subcutaneous delivery, effector function.
Current Pharmaceutical Design
Title:Rheumatology: A Force for Change in Monoclonal Antibodies
Volume: 21 Issue: 17
Author(s): David C. Lowe and Tristan J. Vaughan
Affiliation:
Keywords: Antibody, rheumatology, affinity maturation, subcutaneous delivery, effector function.
Abstract: Monoclonal antibodies have undergone a radical evolutionary journey over the last 25 years, with advances in molecular biology, process development and drug formulation underpinning their rise to becoming one of the most efficacious and economically important class of drug today. The success of antibodies for the treatment of rheumatological conditions, such as rheumatoid arthritis in particular, has driven the biopharmaceutical industry to optimize all aspects of therapeutic antibody discovery and development, in order to provide further benefits for patients over and above marketed treatments, via increased clinical efficacy and patient convenience. Recent advances in many of the key aspects of antibody design that are driving this evolution, such as affinity optimization, effector function modulation, pharmacokinetic engineering, as well as developments in subcutaneous drug delivery, are reviewed here.
Export Options
About this article
Cite this article as:
C. Lowe David and J. Vaughan Tristan, Rheumatology: A Force for Change in Monoclonal Antibodies, Current Pharmaceutical Design 2015; 21 (17) . https://dx.doi.org/10.2174/1381612821666150310142202
DOI https://dx.doi.org/10.2174/1381612821666150310142202 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Systemic Lupus Erythematosus: Old and New Susceptibility Genes versus Clinical Manifestations
Current Genomics Integration of Virtual and High Throughput Screening in Lead Discovery Settings
Combinatorial Chemistry & High Throughput Screening Effects of Chrisotherapeutic Gold Compounds on Prostaglandin E2 Production
Current Drug Targets - Inflammation & Allergy Endothelial Progenitor Cells: A Vascular Perspective for Inflammatory Rheumatic Disorders
Current Rheumatology Reviews Meet Our Associate Editorial Board Member
Current Psychopharmacology Palmitoylethanolamide in Homeostatic and Traumatic Central Nervous System Injuries
CNS & Neurological Disorders - Drug Targets Small Molecule Antagonists of the CXCR2 and CXCR1 Chemokine Receptors as Therapeutic Agents for the Treatment of Inflammatory Diseases
Current Topics in Medicinal Chemistry Fragment Based Drug Design: From Experimental to Computational Approaches
Current Medicinal Chemistry The Influence of Different Disease States on Rituximab Pharmacokinetics
Current Drug Metabolism Genetic and Non-Genetic Determinants of the Pharmacological Activity of Statins
Current Drug Metabolism Multi-Target Directed Compounds with Antioxidant and/or Anti- Inflammatory Properties as Potent Agents for Alzheimer’s Disease
Medicinal Chemistry Inhibitors of TACE and Caspase-1 As Anti-inflammatory Drugs
Current Medicinal Chemistry Therapeutic Targets of Misguided T Cells in Systemic Lupus Erythematosus
Current Drug Targets - Inflammation & Allergy Adenoviral Vector-Mediated Gene Transfer for Human Gene Therapy
Current Gene Therapy The Role of COX-2 in Heart Pathology
Cardiovascular & Hematological Agents in Medicinal Chemistry Inhibition of Histone Deacetylases: A Pharmacological Approach to the Treatment of Non-Cancer Disorders
Current Topics in Medicinal Chemistry Microbial Agent – Fungus
Current Rheumatology Reviews Exercise and Cognitive-Behavioural Treatment in Fibromyalgia Syndrome
Current Pharmaceutical Design Hecogenin Acetate Inhibits Reactive Oxygen Species Production and Induces Cell Cycle Arrest and Senescence in the A549 Human Lung Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry Biologics for the Treatment of Juvenile Idiopathic Arthritis
Current Medicinal Chemistry